OPTIMISATION OF ANTIBIOTIC USE IN A COUNTY HOSPITAL
DI-037
RISK OF HYPERTENSION IN PATIENTS TREATED WITH MIRABEGRON. STRATEGY FOR PRIORITISATION OF A DRUG SAFETY WARNING
DI-036
TOXICITY IN ONCOLOGY: AN ANALYSIS
DI-035
INTRAVITREAL AFLIBERCEPT INJECTIONS FOR TREATING WET AGE RELATED MACULAR DEGENERATION UNRESPONSIVE TO OTHER ANTIVASCULAR ENDOTHELIAL GROWTH FACTORS: INITIAL EXPERIENCE IN ROUTINE CLINICAL PRACTICE
DI-034
DRUG USAGE EVALUATION OF ABIRATERONE IN METASTASIC CASTRATION RESISTANT PROSTATE CANCER: 4 YEARS OF EXPERIENCE
DI-032
STUDY OF EFFECTIVENESS AND SAFETY OF FOSCARNET IN CYTOMEGALOVIRUS TREATMENT IN HAEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
DI-031
ACUTE PANCREATITIS AND HYPERBILIRUBINAEMIA POSSIBLY ASSOCIATED WITH RIBAVIRIN ADMINISTRATION AND NEW DIRECT ANTIVIRAL AGENTS
DI-030
IMPACT OF LAST GUIDELINES ON ANTIEMETIC PRESCRIPTIONS IN A FRENCH UNIVERSITY HOSPITAL
DI-029
SEVERE HYPONATREMIA INDUCED BY ESCITALOPRAM: A CASE REPORT
DI-028
NOVEL ORAL ANTIPLATELET AGENTS IN ACUTE CORONARY SYNDROME. PRESCRIPTION PROFILE IN A TERTIARY HOSPITAL
DI-026
THERAPEUTIC EDUCATION AND LONG TERM CORTICOTHERAPY: PATIENTS’ EXPECTATIONS
DI-024
AN INDEPENDENT STUDY ABOUT OVER THE COUNTER MEDICINES TO ANALYSE PARENTS’ AWARENESS FOR PAEDIATRIC USE
DI-023
ANALYSIS OF INTRAVENOUS IMMUNOGLOBULIN USE IN A TERTIARY HOSPITAL AND EVALUATION OF ITS ECONOMIC IMPACT
DI-022
REAL LIFE EFFECTIVENESS AND SAFETY OF LENALIDOMIDE IN THE TREATMENT OF MULTIPLE MYELOMA
DI-021
SAFETY PROFILE OF THE NEW DIRECT ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS
